Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Immunogenicity and Efficacy of Pfs230D1M-EPA/AS01 Vaccine in Mali
NCT03917654Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2019
- Primary completion
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Pfs230D1M-EPA + AS01 in malaria (8 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Participants With Local and Systemic Adverse Events. Started Apr 2019; status: completed.
02
Drugs
Pfs230D1M-EPA + AS01
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03917654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917654.